• Novartis' spinal muscular atrophy drug approved in Canada

    Health Canada has approved Zolgensma for the treatment of pediatric spinal muscular atrophy patients with three or less copies of the SMN2 gene, or infantile-onset SMA.
  • N2 Biomedical appoints new CEO

    Eric Tobin has been announced as CEO of N2 Biomedical, a company providing coating and surface treatment for medical devices, according to a Dec. 2 press release.
  • Stem cells in spine, orthopedics: 6 notes for surgeons

    A landmark clinical trial was announced in November when a $9 million grant was provided for the first human study using stem cells to treat a spinal disorder that occurs in babies in the womb.

Featured Webinars

Featured Whitepapers